FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.

FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR |
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
The world didn’t end on Jan. 1, 2000. The Y2K bug didn’t crash airplanes and liquidate bank assets. We were, overall, hopeful for the future—a new millennium full of futuristic visions of a techno-utopia. Fast forward a quarter of a century and we now live in that technologically advanced age that once seemed so far…
ACR Convergence 2024—In a wide-ranging and engaging discussion, members of the Association of Rheumatology Professionals (ARP) tracked their progress over the years across clinical practice, research production and representation in the field, while outlining challenges and opportunities to come. The session at ACR Convergence included a panel and an audience full of past presidents of…
Yvonne M. van der Kraan, BSc, Andrew Lui, PT, DPT, Anneke Spoorenberg, MD, Suzanne Arends, PhD, & Lianne S. Gensler, MD |
‘Physical therapy is a mainstay of managing rheumatic diseases, but what’s the evidence, how do we monitor, and what types of therapy should we advocate?’ asks Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Here, we provide some practical recommendations for the everyday rheumatologist.’ Physical activity, including occupational and recreational activities, is one of…
It’s dark. It’s cold. And it’s 5 p.m. here in Iowa. If that sounds rather bleak to you, I wouldn’t blame you. But to Stella, my 12-year-old canine companion, it’s a wonderland. She’s half-Shetland sheepdog and half-American Eskimo, so the colder and snowier it is, the more she feels at home. And although I do…
Jeffrey Curtis, MD, MS, MPH |
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
At a ACR Convergence 2024 session, experts discussed key characteristics, diagnostic challenges & treatment considerations for neurosarcoidosis.
At this ACR Convergence 2024 session, the focus was on the identification & treatment of a newly identified syndrome of undifferentiated recurrent fever (SURF).
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.